Skip to content

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Search...

About
- Annual Report
- Who We Are
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- FAQ
Why New TB Drugs
R&D
Access
News

Partnerships

Doris Macharia Elected President of TB Alliance’s Global TB Stakeholders, Joins Board of Directors

March 2, 2026

Global health leader brings deep expertise in advancing children’s health, HIV, and global health equity NEW YORK (March 2, 2026)—TB

TB Alliance Announces New Collaboration with Novartis to Advance the Research and Development of Telacebec for Leprosy

January 30, 2026

New collaboration aims to advance innovation for a neglected and stigmatizing disease affecting hundreds of thousands worldwide NEW YORK (January

TB Alliance and Lupin Announce Collaboration to Advance and Commercialize Telacebec for Multiple Neglected Diseases

January 30, 2026

Partnership will support the development of investigational drug telacebec for the treatment of tuberculosis, leprosy, and Buruli ulcer NEW YORK

TB Alliance and Asian Development Bank Forge Strategic Partnership to Strengthen Regional Efforts Against Tuberculosis

December 19, 2025

New York, USA and Manila, Philippines — [Date] — TB Alliance and the Asian Development Bank (ADB) have announced a

About
Why New TB Drugs
R&D
Access
News

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328

Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list

Email Address

© The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy

Treat 2,037,998 People

In the first fifteen years following BPaL’s approval, more than 2 million people treated for drug-resistant TB will be treated with BPaL/M. This means millions of people will benefit from improved treatment outcomes and experiences.

Restore 5,120,433 healthy life years

When TB doesn’t kill, it often leaves people with long periods of disability. By curing drug-resistant TB faster and more effectively, BPaL/M helps people not only survive, but recover faster, and avoid long term disabilities. That means fewer years lost to illness and more people living fully again, faster. In its first 15 years of approval, BPaL/M will result in people experiencing more than 5 million more healthy years of life.

Save an Additional 191,222 lives

BPaL/M has higher treatment success rates than previous therapies and use of these regimens is rapidly scaling up globally. In its first 15 years of approval, BPaL/M will save an additional 190,000 lives by replacing older treatments with lower success rates.

Save the world $1.29B USD

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people receiving treatment.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.

179,697 more people will complete treatment

Traditionally, many people receiving treatment for drug-resistant TB did not complete therapy. This was often due to the length and side effects of treatments. Those who don’t complete treatment may remain contagious and infect others, as well as suffer increased disability or death. In its first 15 years of approval, BPaL/M will lead to nearly 180,000 additional people completing treatment.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” In its first 15 years of approval, BPaL/M will lead to more than 330,000 additional people with drug-resistant TB being successfully treated.